mitomycin has been researched along with Angiogenesis, Pathologic in 18 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the potential of colchicine to improve bleb function after trabeculectomy." | 7.91 | The effectiveness of colchicine combined with mitomycin C to prolong bleb function in trabeculectomy in rabbits. ( Akaishi, T; Kokubun, T; Nakamura, M; Nakazawa, T; Omodaka, K; Sato, K; Shiga, Y; Shimazaki, A; Tsuda, S; Yamamoto, K, 2019) |
| "Ellagic acid (EA) is a polyphenolic compound that can be found as a naturally occurring hydrolysis product of ellagitannins in pomegranates, berries, grapes, green tea and nuts." | 5.43 | Ellagic Acid Inhibits Bladder Cancer Invasiveness and In Vivo Tumor Growth. ( Atzori, MG; Bonanno, E; Ceci, C; Cicconi, R; de Martino, MG; Graziani, G; Lacal, PM; Mattei, M; Miano, R; Scimeca, M; Tentori, L; Vespasiani, G, 2016) |
| "We describe a case of a 37-year-old veteran with recurrent conjunctival hyperemia 5 years after an eye-whitening conjunctivectomy procedure with mitomycin C who desired to have a repeat procedure by the original surgeon." | 3.96 | White Sclera Painted Contact Lens for Masking of Conjunctival Neovascularization and Hyperemia Following Cosmetic Eye Whitening Procedure. ( Magone, MT; Singh, GA, 2020) |
| "To investigate the potential of colchicine to improve bleb function after trabeculectomy." | 3.91 | The effectiveness of colchicine combined with mitomycin C to prolong bleb function in trabeculectomy in rabbits. ( Akaishi, T; Kokubun, T; Nakamura, M; Nakazawa, T; Omodaka, K; Sato, K; Shiga, Y; Shimazaki, A; Tsuda, S; Yamamoto, K, 2019) |
| "The primary endpoint measured was bleb morphology and vascularity using the Moorfields Bleb Grading System." | 2.75 | Bleb morphology and vascularity after trabeculectomy with intravitreal ranibizumab: a pilot study. ( Kahook, MY, 2010) |
| "The healing and scarring determine the percentage of patients achieving low final intraocular pressures (IOPs) that are associated with virtually no glaucoma progression." | 2.44 | Modulation of wound healing during and after glaucoma surgery. ( Brocchini, S; Dahlmann-Noor, A; Georgoulas, S; Khaw, PT, 2008) |
| "Ellagic acid (EA) is a polyphenolic compound that can be found as a naturally occurring hydrolysis product of ellagitannins in pomegranates, berries, grapes, green tea and nuts." | 1.43 | Ellagic Acid Inhibits Bladder Cancer Invasiveness and In Vivo Tumor Growth. ( Atzori, MG; Bonanno, E; Ceci, C; Cicconi, R; de Martino, MG; Graziani, G; Lacal, PM; Mattei, M; Miano, R; Scimeca, M; Tentori, L; Vespasiani, G, 2016) |
| "5 mg/kg), or cisplatin (4 mg/kg, by one shot) to TNP (120-140 mg/kg) with a 6-7 fractionated dosing schedule reduced s." | 1.29 | Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470) and cytotoxic agents in mice. ( Kakinuma, H; Kato, T; Matsuda, Y; Sato, K, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (11.11) | 18.7374 |
| 1990's | 8 (44.44) | 18.2507 |
| 2000's | 4 (22.22) | 29.6817 |
| 2010's | 3 (16.67) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Singh, GA | 1 |
| Magone, MT | 1 |
| Kokubun, T | 1 |
| Yamamoto, K | 1 |
| Sato, K | 2 |
| Akaishi, T | 1 |
| Shimazaki, A | 1 |
| Nakamura, M | 1 |
| Shiga, Y | 1 |
| Tsuda, S | 1 |
| Omodaka, K | 1 |
| Nakazawa, T | 1 |
| Ceci, C | 1 |
| Tentori, L | 1 |
| Atzori, MG | 1 |
| Lacal, PM | 1 |
| Bonanno, E | 1 |
| Scimeca, M | 1 |
| Cicconi, R | 1 |
| Mattei, M | 1 |
| de Martino, MG | 1 |
| Vespasiani, G | 1 |
| Miano, R | 1 |
| Graziani, G | 1 |
| Georgoulas, S | 1 |
| Dahlmann-Noor, A | 1 |
| Brocchini, S | 1 |
| Khaw, PT | 1 |
| Kahook, MY | 1 |
| Yi, J | 1 |
| Liao, X | 1 |
| Yang, Z | 1 |
| Li, X | 1 |
| Lutty, GA | 1 |
| Liu, SH | 1 |
| Prendergast, RA | 1 |
| Yanai, S | 1 |
| Okada, H | 1 |
| Saito, K | 1 |
| Kuge, Y | 1 |
| Misaki, M | 1 |
| Ogawa, Y | 1 |
| Toguchi, H | 1 |
| Kato, T | 1 |
| Kakinuma, H | 1 |
| Matsuda, Y | 1 |
| Konno, H | 3 |
| Tanaka, T | 3 |
| Matsuda, I | 1 |
| Kanai, T | 2 |
| Maruo, Y | 1 |
| Nishino, N | 1 |
| Nakamura, S | 3 |
| Baba, S | 1 |
| Pepper, MS | 1 |
| Ferrara, N | 1 |
| Orci, L | 1 |
| Montesano, R | 1 |
| Harris, AL | 1 |
| Horak, E | 1 |
| Gaspar, AZ | 1 |
| Flammer, J | 1 |
| Hendrickson, P | 1 |
| Shishido, T | 1 |
| Yasoshima, T | 1 |
| Denno, R | 1 |
| Sato, N | 1 |
| Hirata, K | 1 |
| Takei, H | 1 |
| Iino, Y | 1 |
| Horiguchi, J | 1 |
| Maemura, M | 1 |
| Koibuchi, Y | 1 |
| Nagaoka, H | 1 |
| Yokoe, T | 1 |
| Oyama, T | 1 |
| Morishita, Y | 1 |
| Matsumoto, K | 1 |
| Baba, M | 2 |
| Kamiya, K | 2 |
| Ohba, K | 1 |
| Ohta, M | 1 |
| Oba, K | 1 |
| Kaneko, T | 1 |
| Syouji, T | 1 |
| Igarashi, A | 1 |
| Tanaka, NG | 1 |
| Sakamoto, N | 1 |
| Tohgo, A | 1 |
| Nishiyama, Y | 1 |
| Ogawa, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Occlusion Prevention for Trabeculectomy Procedures Using Combination Ranibizumab and Mitomycin C (MMC) During Surgery (OCTOPUS Study)[NCT00661583] | Phase 1/Phase 2 | 30 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To assess ocular adverse events of combination ranibizumab and MMC therapy at 6 months (NCT00661583)
Timeframe: 6 months
| Intervention | Number of Reported Adverse Events (Number) |
|---|---|
| Ranibizumab Alone | 0 |
| Ranibizumab and MMC | 0 |
| MMC Alone | 0 |
To determine percent of subjects with a qualified success and viable bleb at 6 months (IOP between 6mm Hg and 22 mm Hg with pressure controlled with and without adjunctive medications) (NCT00661583)
Timeframe: 6 months
| Intervention | percentage of subjects (Number) |
|---|---|
| Ranibizumab Alone | 100 |
| Ranibizumab and MMC | 100 |
| MMC Alone | 100 |
Mean change in in intraocular pressure at 3 months and at 6 months (NCT00661583)
Timeframe: 6 months
| Intervention | mmHg (Mean) | |
|---|---|---|
| month 3 minus baseline | month 6 minus baseline | |
| MMC Alone | -8.35 | -8.00 |
| Ranibizumab Alone | -6.40 | -6.60 |
| Ranibizumab and MMC | -6.40 | -4.90 |
Mean change in visual acuity in logMAR. (NCT00661583)
Timeframe: 6 months
| Intervention | logMAR (Mean) | |
|---|---|---|
| Month 3 minus baseline | Month 6 minus baseline | |
| MMC Alone | 0.13 | 0.13 |
| Ranibizumab Alone | -0.01 | -0.05 |
| Ranibizumab and MMC | 0.01 | 0.05 |
2 reviews available for mitomycin and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Modulation of wound healing during and after glaucoma surgery.
Topics: Antibiotics, Antineoplastic; Cicatrix; Dendrimers; Fibroblasts; Filtering Surgery; Glaucoma; Humans; | 2008 |
Growth factors and angiogenesis in breast cancer.
Topics: Antigens, Differentiation, Myelomonocytic; Breast Neoplasms; Drug Resistance; ErbB Receptors; Female | 1993 |
1 trial available for mitomycin and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Bleb morphology and vascularity after trabeculectomy with intravitreal ranibizumab: a pilot study.
Topics: Aged; Alkylating Agents; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Hu | 2010 |
15 other studies available for mitomycin and Angiogenesis, Pathologic
| Article | Year |
|---|---|
White Sclera Painted Contact Lens for Masking of Conjunctival Neovascularization and Hyperemia Following Cosmetic Eye Whitening Procedure.
Topics: Adult; Alkylating Agents; Color; Conjunctiva; Contact Lenses, Hydrophilic; Cosmetic Techniques; Huma | 2020 |
The effectiveness of colchicine combined with mitomycin C to prolong bleb function in trabeculectomy in rabbits.
Topics: Alkylating Agents; Animals; Blister; Colchicine; Drug Therapy, Combination; Eye Diseases; Male; Mito | 2019 |
Ellagic Acid Inhibits Bladder Cancer Invasiveness and In Vivo Tumor Growth.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B7-H1 A | 2016 |
Study on the changes in microvessel density in hepatocellular carcinoma following transcatheter arterial chemoembolization.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, | 2001 |
Angiogenic lymphokines of activated T-cell origin.
Topics: Animals; Concanavalin A; Cornea; Lymphocyte Activation; Lymphokines; Male; Mitomycin; Mitomycins; Ne | 1983 |
Antitumor effect of arterial administration of a medium-chain triglyceride solution of an angiogenesis inhibitor, TNP-470, in rabbits bearing VX-2 carcinoma.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Caprylates; Ca | 1995 |
Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470) and cytotoxic agents in mice.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Body Weight; C | 1994 |
Comparison of the inhibitory effect of the angiogenesis inhibitor, TNP-470, and mitomycin C on the growth and liver metastasis of human colon cancer.
Topics: Animals; Antibiotics, Antineoplastic; Body Weight; Cell Division; Colonic Neoplasms; Cyclohexanes; H | 1995 |
Leukemia inhibitory factor (LIF) inhibits angiogenesis in vitro.
Topics: Adrenal Cortex; Animals; Aorta; Cattle; Cell Division; Cell Movement; Cells, Cultured; Dose-Response | 1995 |
Regression of rubeosis iridis after trabeculectomy combined with mitomycin-C.
Topics: Aged; Antibiotics, Antineoplastic; Combined Modality Therapy; Female; Follow-Up Studies; Glaucoma; H | 1996 |
Inhibition of liver metastasis of human gastric carcinoma by angiogenesis inhibitor TNP-470.
Topics: Animals; Antibiotics, Antineoplastic; Cell Division; Cyclohexanes; Female; Humans; Liver Neoplasms; | 1996 |
Angiogenesis and stromal fibronectin expression in invasive breast carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 1998 |
Combination therapy with vascular endothelial growth factor neutralizing antibody and mitomycin C on human gastric cancer xenograft.
Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Body Weight; Cell Divi | 2000 |
Effect of combination therapy with matrix metalloproteinase inhibitor MMI-166 and mitomycin C on the growth and liver metastasis of human colon cancer.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Body Weight; C | 2001 |
Inhibitory effects of anti-angiogenic agents on neovascularization and growth of the chorioallantoic membrane (CAM). The possibility of a new CAM assay for angiogenesis inhibition.
Topics: Allantois; Animals; Chick Embryo; Chorion; Cortisone; Drug Evaluation, Preclinical; Extraembryonic M | 1986 |